Solid Biosciences (SLDB) Assets Average (2018 - 2026)

Solid Biosciences has reported Assets Average for 9 years, with the latest figure at $327.7 million in Q1 2026.

• Quarterly Assets Average rose 23.07% year-over-year to $327.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $327.7 million (up 23.07% YoY) and the FY2025 annual result came in at $210.6 million, up 19.12% from the prior year.
• Assets Average grew to $327.7 million in Q1 2026 per SLDB's latest filing, from $253.2 million in the prior quarter.
• Over five years, Assets Average peaked at $327.7 million in Q1 2026 and troughed at $174.8 million in Q4 2023.
• A 5-year average of $236.0 million and a median of $221.4 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average fell 24.51% in 2022, then soared 35.97% in 2025.
• Over 5 years, Assets Average stood at $222.4 million in 2022, then declined by 21.37% to $174.8 million in 2023, then advanced by 14.53% to $200.2 million in 2024, then climbed by 26.46% to $253.2 million in 2025, then gained by 29.42% to $327.7 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $327.7 million, $253.2 million, and $291.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.